153 related articles for article (PubMed ID: 36419886)
1. Case Report:
Mauri G; Patelli G; Gori V; Lauricella C; Mussolin B; Amatu A; Bencardino K; Tosi F; Bonazzina E; Bonoldi E; Bardelli A; Siena S; Sartore-Bianchi A
Front Oncol; 2022; 12():1030232. PubMed ID: 36419886
[TBL] [Abstract][Full Text] [Related]
2. MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.
Chuang J; Wang C; Guo Y; Valenzuela V; Wu J; Fakih M
Clin Colorectal Cancer; 2021 Mar; 20(1):72-78. PubMed ID: 33436306
[TBL] [Abstract][Full Text] [Related]
3. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
4. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
5. MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E.
Tan X; Wu Z; Chen M
Onco Targets Ther; 2024; 17():307-312. PubMed ID: 38617091
[TBL] [Abstract][Full Text] [Related]
6. RAS and BRAF in metastatic colorectal cancer management.
Gong J; Cho M; Fakih M
J Gastrointest Oncol; 2016 Oct; 7(5):687-704. PubMed ID: 27747083
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
8. Corrigendum: Case report:
Mauri G; Patelli G; Gori V; Lauricella C; Mussolin B; Amatu A; Bencardino K; Tosi F; Bonazzina E; Bonoldi E; Bardelli A; Siena S; Sartore-Bianchi A
Front Oncol; 2023; 13():1147497. PubMed ID: 37056342
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with
Martini G; Ciardiello D; Napolitano S; Martinelli E; Troiani T; Latiano TP; Avallone A; Normanno N; Di Maio M; Maiello E; Ciardiello F
Front Oncol; 2023; 13():1069370. PubMed ID: 36860319
[TBL] [Abstract][Full Text] [Related]
10. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis.
Mao C; Liao RY; Qiu LX; Wang XW; Ding H; Chen Q
Mol Biol Rep; 2011 Apr; 38(4):2219-23. PubMed ID: 20857202
[TBL] [Abstract][Full Text] [Related]
12. MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines.
Kim JE; Kim KK; Kim SY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
J Cancer; 2017; 8(12):2263-2268. PubMed ID: 28819429
[No Abstract] [Full Text] [Related]
13. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies.
Cui D; Cao D; Yang Y; Qiu M; Huang Y; Yi C
Mol Biol Rep; 2014 Mar; 41(3):1291-8. PubMed ID: 24390240
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS.
Liu J; Hu J; Cheng L; Ren W; Yang M; Liu B; Xie L; Qian X
Onco Targets Ther; 2016; 9():557-65. PubMed ID: 26869800
[TBL] [Abstract][Full Text] [Related]
15. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of anti-EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild-type metastatic colorectal cancer: A meta-analysis.
Sun H; Li Y; Su Y; Wu X; Zhou X; Han J; Li J
J Evid Based Med; 2019 Nov; 12(4):300-312. PubMed ID: 31596544
[TBL] [Abstract][Full Text] [Related]
17. KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy.
Favazza LA; Parseghian CM; Kaya C; Nikiforova MN; Roy S; Wald AI; Landau MS; Proksell SS; Dueker JM; Johnston ER; Brand RE; Bahary N; Gorantla VC; Rhee JC; Pingpank JF; Choudry HA; Lee K; Paniccia A; Ongchin MC; Zureikat AH; Bartlett DL; Singhi AD
Mod Pathol; 2020 Sep; 33(9):1832-1843. PubMed ID: 32376853
[TBL] [Abstract][Full Text] [Related]
18. Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial.
Germani MM; Vetere G; Giordano M; Ciracì P; Capone I; Tamborini E; Conca E; Busico A; Pietrantonio F; Piva VM; Boccaccino A; Simionato F; Bortolot M; Manca P; Lonardi S; Conca V; Borelli B; Carullo M; Del Re M; Fontanini G; Rossini D; Cremolini C
Front Oncol; 2023; 13():1307545. PubMed ID: 38406172
[TBL] [Abstract][Full Text] [Related]
19. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer.
Johnson B; Loree JM; Jacome AA; Mendis S; Syed M; Morris Ii VK; Parseghian CM; Dasari A; Pant S; Raymond VM; Vilar E; Overman M; Kee B; Eng C; Raghav K; Kopetz S
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914034
[TBL] [Abstract][Full Text] [Related]
20. CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated
Napolitano S; Martini G; Ciardiello D; Di Maio M; Normanno N; Avallone A; Martinelli E; Maiello E; Troiani T; Ciardiello F
Front Oncol; 2022; 12():940523. PubMed ID: 35832541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
